Holen Sie sich die Stockscreener-App
0.9785
3.01%
0.0286
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus
Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan
Scienture Holdings Divests Subsidiaries to Tollo Health - MSN
Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa
Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - MarketScreener
Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener
Scienture Holdings divests subsidiaries for $5 million - Investing.com
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times
Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan
SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa
Scienture Holdings gears up for specialty pharma launches - Investing.com
Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks
Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK
Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView
Major Pharma Transformation: Scienture Reveals Two FDA-Approved Drugs and $480M+ Market Opportunity - Stock Titan
Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register
Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times
Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan
3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scienture Holdings announces draw on Equity Line of Credit - MSN
Scienture announces draaw on Equity Line of Credit - TipRanks
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times
Organovo Announces Reverse Stock Split - The Manila Times
FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan
Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics
What's Going On With Scienture Shares Tuesday? - Benzinga
FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times
Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan
Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail
Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Scienture Holdings Inc (SCNX) Stock Behavior Isn’t As Predictable As You Think - Stocks Register
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Scienture Holdings appoints new CFO, stockholders vote at annual meeting By Investing.com - Investing.com Australia
Scienture Holdings appoints new CFO, stockholders vote at annual meeting - Investing.com
Scienture Holdings Appoints New CFO Eric Sherb - TipRanks
Scienture Holdings Secures Exclusive Naloxone Agreement - TipRanks
United States shares higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com
Best Stocks Under $5 Right Now - Benzinga
Nasdaq Down Over 400 Points; Kroger Posts Upbeat Earnings - Benzinga
0.00%
4.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):